Global Urology Supplements Market Trends Analysis Report 2024-2030: Asia Pacific Emerges as Dominant Force, Multi-Ingredient Supplements Lead
30. April 2024 05:36 ET
|
Research and Markets
Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Global Urology Supplements Market Size, Share & Trends Analysis Report by Type (Multi-ingredient, Single Ingredient), Application (Urinary Tract...
Urinary Tract Infection Therapeutics Market Size is projected to reach USD 11.85 billion by 2031, growing at a CAGR of 3.2%: Straits Research
02. August 2023 09:55 ET
|
Straits Research
New York, United States, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Patients with critical conditions and diabetes are susceptible to numerous infectious diseases. The individual is prone to urinary tract...
OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference
20. Juni 2023 07:30 ET
|
OpGen, Inc.
‘Multi-Center Clinical Trial Using a Novel Semi-Quantitative Multiplex-PCR Based Diagnostic Panel for Urinary Tract Specimens’ presented on June 17th, 2023Presentation focused on primary study...
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
18. April 2023 16:30 ET
|
OpGen, Inc.
Fisher Healthcare, a part of Thermo Fisher Scientific, will become the non-exclusive national laboratory distribution partner alongside OpGen, Inc.’s direct sales in the U.S. for the Unyvero A50...
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel
18. April 2023 07:30 ET
|
OpGen, Inc.
Based on large multi-center study with over 1,800 patient samplesPrimary endpoint for Unyvero UTI for urinary tract infection was successfully met and shows overall weighted average sensitivity of...
CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
30. März 2023 14:25 ET
|
OpGen, Inc.
ROCKVILLE, Md., March 30, 2023 (GLOBE NEWSWIRE) -- In a release published March 29, 2023 under the same headline by OpGen, Inc. (Nasdaq: OPGN), the financial tables were incorrect. The corrected...
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
29. März 2023 16:15 ET
|
OpGen, Inc.
Total revenue for 2022 was approximately $2.6 millionBalance sheet strengthened by recently closed public offering with gross proceeds of $7.5 millionConference call to be held March 29, 2023 at 4:30...
OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth
01. März 2023 07:30 ET
|
OpGen, Inc.
Approximately 5,000 sq. ft. facility houses laboratory and administrative operations under one location for future growth of businessARESdb, the company’s AMR knowledge database, has grown by 28% in...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPRO
05. Juni 2022 17:15 ET
|
The Rosen Law Firm PA
NEW YORK, June 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Spero...
Women's Experiences with Urinary Tract Infections, 2021-2022 Study Report: Usage of UTI At-Home Test Kits has Increased Sharply as has the Likelihood of Future Use
14. April 2022 06:33 ET
|
Research and Markets
Dublin, April 14, 2022 (GLOBE NEWSWIRE) -- The "2021 Study of Women's Experiences with Urinary Tract Infections " report has been added to ResearchAndMarkets.com's offering. Usage of UTI at-home...